A UK audit of screening for the metabolic side effects of antipsychotics in community patients.
about
Management of antipsychotic-related weight gainExcess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas.Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial.Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis.Impact of a nurse-led intervention to improve screening for cardiovascular risk factors in people with severe mental illnesses. Phase-two cluster randomised feasibility trial of community mental health teams.Standards of lithium monitoring in mental health Ttrusts in the UKA well-being support program for patients with severe mental illness: a service evaluation.Monitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness.Physical healthcare of people with severe mental illness: everybody's business!The effectiveness of specialist roles in mental health metabolic monitoring: a retrospective cross-sectional comparison study.Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approachPhysical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Barriers and facilitators to implementation of a metabolic monitoring protocol in hospital and community settings for second-generation antipsychotic-treated youth.Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.Poor monitoring of physical health in patients referred to a mood disorders serviceEnhanced physical health screening for people with severe mental illness in Hong Kong: results from a one-year prospective case series studyMetabolic disturbances independent of body mass in patients with schizophrenia taking atypical antipsychoticsSudden deaths in psychiatric patientsPhysical Health and Dual Diagnosis.The role of boundary spanners in delivering collaborative care: a process evaluationScreening for the metabolic side effects of antipsychotic medication: findings of a 6-year quality improvement programme in the UK.Predictors of vocational status in schizophrenia patients--Results from the Polish nationwide survey.Is Metabolic Syndrome On the Radar? Improving Real-Time Detection of Metabolic Syndrome and Physician Response by Computerized Scan of the Electronic Medical RecordImproving the Physical Health Monitoring of City & Hackney Assertive Outreach Service PatientsImproving blood and ECG monitoring among patients prescribed regular antipsychotic medicationsExploring primary care activities in ACT teamsMetabolic and cardiovascular adverse effects associated with antipsychotic drugs.Improving prescribing practice in psychiatry: the experience of the Prescribing Observatory for Mental Health (POMH-UK).Perceptions of barriers to physical health care for people with serious mental illness: a review of the international literature.Atypical antipsychotics and diabetic ketoacidosis: a review.Diabetes mellitus and severe mental illness: mechanisms and clinical implications.Treating complexity: collaborative care for multiple chronic conditions.The prevention of diabetes and cardiovascular disease in people with schizophrenia.Care coordinator views and experiences of physical health monitoring in clients with severe mental illness: A qualitative study.Assessing clinicians' perspectives about the identification and management of antipsychotic medication side-effects: Psychometric evaluation of a survey questionnaire.Increased cardiovascular mortality in people with schizophrenia: a 24-year national register study.BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment.Effectiveness and cost-effectiveness of a cardiovascular risk prediction algorithm for people with severe mental illness (PRIMROSE).Screening for the metabolic syndrome in Australia: a national survey of psychiatrists' attitudes and reported practice in patients prescribed antipsychotic drugs.Metabolic Syndrome Screening and Assertive Community Treatment: A Quality Improvement Study.
P2860
Q24610124-27925B05-5BED-4C2B-A34A-B2EB13DACC4FQ30379171-94445851-3AEC-4668-ADA6-4C7F5EA83F79Q30949176-52260595-54B3-4D30-9FED-3B6E9AC7D562Q33371995-B658FBDD-70C0-4F40-92D8-A9B822E4A4DEQ33539405-C66B2AAF-46E6-4A63-979A-3CFB5C33885EQ33715759-8ED0A147-B450-4C45-8798-B8A7026EEA19Q33850375-5AC563B0-1716-43F9-A274-FF9E07102C53Q33889282-4A452845-B2A4-4A20-B27F-82D69CFA4EF1Q34127836-D00CDD88-1207-4BFB-8D79-940A296BA3C3Q34143764-1F0D40E1-3361-4DEC-9B67-DE9E1D8566B3Q34464293-22A64E01-4DBF-45BA-899A-82BA4ECCB03CQ34623350-7B48BE62-AB7B-4D48-A3A0-80159B995FACQ34900812-F6129493-384B-4F4F-B948-993A435AB2B3Q35016170-BEB8D558-4358-4218-9637-2897537217A1Q35044181-C4C234AE-A0CF-41FB-8EDA-F6346A7C9AA0Q35103964-2470BF12-8187-4134-82A5-2B02C286AF7BQ35330607-C8DC6A86-BD51-4BC9-AB8F-D04E2777F2A9Q35834580-D1F4FD28-D5F4-4689-B3AB-29BA6B8DF843Q36009165-0D31BC81-DD98-4E45-829E-EC593E2E2E0AQ36090291-7EE3FE4B-9B71-4031-8ADF-6A651D84D046Q36163545-906B3C50-E8AC-45C8-851C-E6E7412C5A0DQ36432813-55513939-10C5-4705-9D55-41C46BD62A77Q36921831-64E251E5-235A-4DDC-82CA-89263ACD673BQ37105473-F43F1BD0-D34B-4337-960A-C93C5029368FQ37294187-C9C531CE-E1D4-4539-B485-B7B06C6192ACQ37669657-43199950-6F05-4351-B5FD-F11AC9614932Q37947095-53366CBD-E45B-43AB-8B0C-C1F514334F7AQ37949397-83C82277-F5DD-4DB5-AD42-089AF5000934Q38059244-6324BDBD-E6DD-48D2-9B8B-23001123D56BQ38076320-9A60AAA7-0E36-4BE4-A4F5-6B1A277AEA6EQ38274901-6CCCB299-C3D1-4044-91D0-36BEE5E820CDQ38305592-CEAA0A63-B021-447C-8149-996B5C02FDC0Q38482029-E6D5208B-494A-4FB5-9FFA-2B74D9874B42Q38641592-90DE7C5E-3872-4785-8BAE-9211AA1A4C32Q38719003-95D7CAF0-C417-4192-BED2-971C7CD60E9FQ38744157-0CC38529-FCBD-47C4-9D7D-DD48BD62C3F7Q38826206-ED48553C-952C-4A28-801A-8DF4A0FDC0EDQ40055142-34999D04-698E-4309-AA8F-49BDD42C02E4Q40243708-4C8530BE-E54A-4AB0-B0D2-154274970383Q40306195-15E67076-90B2-46B8-8799-1D46E09E3E32
P2860
A UK audit of screening for the metabolic side effects of antipsychotics in community patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 May 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A UK audit of screening for th ...... chotics in community patients.
@en
A UK audit of screening for th ...... chotics in community patients.
@nl
type
label
A UK audit of screening for th ...... chotics in community patients.
@en
A UK audit of screening for th ...... chotics in community patients.
@nl
prefLabel
A UK audit of screening for th ...... chotics in community patients.
@en
A UK audit of screening for th ...... chotics in community patients.
@nl
P2093
P2860
P356
P1476
A UK audit of screening for th ...... chotics in community patients.
@en
P2093
Carol Paton
Elizabeth Hancock
Mary-Rose Cavanagh
Thomas R E Barnes
UK Prescribing Observatory for Mental Health
P2860
P304
P356
10.1093/SCHBUL/SBM038
P407
P50
P577
2007-05-04T00:00:00Z